section name header

Indications ⬇

High Alert


Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Hemat: anemia, leukopenia, neutropenia, thrombocytopenia

Neuro: coma, craniospinal demyelination, dizziness, drowsiness, headache, paresthesia, status epilepticus, amnesia, ataxia, balance disorder, dysgeusia, neuropathy, tremor

Interactions ⬆ ⬇

Drug-drug:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

US Brand Names ⬆ ⬇

Arranon

Action ⬆ ⬇

  • Converted intracellularly to ara-G and then to ara-GTP. In leukemic cells, it is incorporated into DNA, leading to inhibition of DNA synthesis and cell death.
Therapeutic effects:
  • Decreased proliferation of leukemic cells.

Classifications ⬆ ⬇

Therapeutic Classification: antineoplastics

Pharmacologic Classification: antimetabolites

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability. Intracellular conversion is required for activation of prodrug.

Distribution: Extensively distributed.

Metabolism/Excretion: Mostly metabolized intracellularly. Partially eliminated by the kidneys as nelarabine and ara-G.

Half-Life: Unknown.

Canadian Brand Names ⬆ ⬇

Atriance

Time/Action Profile ⬆ ⬇

ROUTEONSETPEAKDURATION
IVunknownend of infusionunknown

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

ne-LAR-a-been

Code ⬆

NDC Code